Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 11:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 149 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Aricept (donepezil hydrochloride) Clear all

Conditions: Healthy
Interventions: Donepezil Hydrochloride, Aricept®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: East Grand Forks, Minnesota

Conditions: Alzheimer's Disease
Interventions: MK-1167, Donepezil, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Hallandale, Florida • Decatur, Georgia • Savannah, Georgia

Conditions: Alzheimer's Disease
Interventions: Donepezil TDS; Drug
Lead sponsor: Corium, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Parkinson's Disease
Interventions: Donepezil; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 30 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Parkinson Disease
Interventions: Donepezil, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Alzheimer Disease
Interventions: Donepezil, Estrogen, Progesterone; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 45 Years to 85 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Mild Cognitive Impairment
Interventions: Donepezil, Atropine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 55 Years to 95 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer's Disease, Dementia
Interventions: Placebo, donepezil (Aricept); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Subjects
Interventions: E2609, itraconazole, rifampin, digoxin, donepezil; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Alzheimer Disease
Interventions: Donepezil, BMS-708163; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cognitive Impairment
Interventions: Aricept; Drug
Lead sponsor: Eisai Limited; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Maywood, Illinois • New York, New York

Conditions: Postoperative Complications, Delirium
Interventions: Donepezil; Drug
Lead sponsor: Indiana University Health; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Alzheimer's Disease
Interventions: placebo, donepezil, ABT-126; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 55 Years to 90 Years
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 8
States / cities: Delray Beach, Florida • Tampa, Florida • West Palm Beach, Florida + 5 more

Conditions: Alzheimer's Disease
Interventions: donepezil; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: Donepezil; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Dementia Alzheimer's Type
Interventions: SAR110894, placebo (for SAR110894), Donepezil; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 27
States / cities: Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more

Conditions: Rett Syndrome
Interventions: dextromethorphan, donepezil hydrochloride; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 1 Year to 15 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alzheimer's Disease
Interventions: Donepezil, AZD3480; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Phoenix, Arizona • Brooksville, Florida • Hallandale, Florida

Conditions: Wound Heal
Interventions: Donepezil, Placebo oral tablet, Topical Zinc Oxide; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 20 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Easton, Maryland

Conditions: Multiple Sclerosis
Interventions: donepezil, glucose; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 56 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Alzheimer's Disease
Interventions: PF-04447943, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Glendale, California • Gainesville, Florida • Hallandale, Florida

Conditions: Healthy Subjects
Interventions: Donepezil plus placebo, Donepezil, Begacestat; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Alzheimer Disease
Interventions: Donepezil TDS Version A, Donepezil TDS Version B, Aricept, Donepezil TDS Version D, Donepezil TDS Version E; Drug
Lead sponsor: Corium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Biomarkers, Pharmacological
Interventions: Huperzine A, Donepezil, Galantamine, Placebo; Drug · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 39 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Silver Spring, Maryland

Search by objective public record fields.

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)

Effects of Cholinergic Augmentation on Measures of Balance and Gait

Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease

Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil

Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

Drug-Drug Interaction Study With Aricept® (Donepezil)

The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

Donepezil in Preventing Delirium in Hospitalized Elderly

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease

Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fasting Conditions

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

The Effect of Donepezil on Wound Healing

Improving Memory in Patients With Multiple Sclerosis

A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

Study Evaluating The Coadministration of Begacestat And Donepezil

A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®

Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance